Kiniksa Pharmaceuticals (KNSA) Scheduled to Post Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is set to announce its earnings results before the market opens on Tuesday, October 29th. Analysts expect the company to announce earnings of ($0.01) per share for the quarter.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The business had revenue of $108.30 million during the quarter, compared to analysts’ expectations of $90.60 million. During the same quarter in the prior year, the business posted ($0.02) earnings per share. The business’s quarterly revenue was up 51.5% on a year-over-year basis. On average, analysts expect Kiniksa Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Kiniksa Pharmaceuticals Stock Up 3.5 %

KNSA stock opened at $26.79 on Wednesday. The business’s 50-day moving average price is $25.61 and its 200-day moving average price is $22.11. The stock has a market cap of $1.90 billion, a P/E ratio of 243.55 and a beta of 0.33. Kiniksa Pharmaceuticals has a twelve month low of $14.12 and a twelve month high of $27.92.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now owns 109,975 shares in the company, valued at $2,955,028.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider John F. Paolini sold 60,692 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $26.12, for a total transaction of $1,585,275.04. Following the sale, the insider now owns 52,038 shares of the company’s stock, valued at $1,359,232.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Eben Tessari sold 17,000 shares of Kiniksa Pharmaceuticals stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total transaction of $456,790.00. Following the completion of the transaction, the chief operating officer now directly owns 109,975 shares of the company’s stock, valued at $2,955,028.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 112,692 shares of company stock worth $2,950,315. Corporate insiders own 54.57% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KNSA. Wedbush lifted their target price on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Tuesday, July 23rd. Jefferies Financial Group initiated coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $33.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.